JPWO2020023323A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020023323A5 JPWO2020023323A5 JP2021504238A JP2021504238A JPWO2020023323A5 JP WO2020023323 A5 JPWO2020023323 A5 JP WO2020023323A5 JP 2021504238 A JP2021504238 A JP 2021504238A JP 2021504238 A JP2021504238 A JP 2021504238A JP WO2020023323 A5 JPWO2020023323 A5 JP WO2020023323A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- drug
- influenza
- influenza virus
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims description 23
- 206010022000 influenza Diseases 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 19
- 241000712461 unidentified influenza virus Species 0.000 claims description 16
- 102000005348 Neuraminidase Human genes 0.000 claims description 10
- 108010006232 Neuraminidase Proteins 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- 239000012216 imaging agent Substances 0.000 claims description 8
- 229960001028 zanamivir Drugs 0.000 claims description 8
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 8
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 6
- 239000002955 immunomodulating agent Substances 0.000 claims description 6
- 230000002584 immunomodulator Effects 0.000 claims description 6
- 229940121354 immunomodulator Drugs 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 6
- -1 therapeutic drug Substances 0.000 claims description 6
- 229940126585 therapeutic drug Drugs 0.000 claims description 6
- JGPXDNKSIXAZEQ-SBBZOCNPSA-N (2s,3s)-3-[[5-fluoro-2-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid Chemical compound C1=C(F)C=C2C(C=3N=C(C(=CN=3)F)N[C@H]3C4CCC(CC4)[C@@H]3C(=O)O)=CNC2=N1 JGPXDNKSIXAZEQ-SBBZOCNPSA-N 0.000 claims description 4
- 125000001894 2,4,6-trinitrophenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O 0.000 claims description 4
- XRVDGNKRPOAQTN-FQEVSTJZSA-N 5-[3-[(1s)-1-(2-hydroxyethylamino)-2,3-dihydro-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3CC[C@@H](C=3C=CC=2)NCCO)=NO1 XRVDGNKRPOAQTN-FQEVSTJZSA-N 0.000 claims description 4
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 4
- 101710091045 Envelope protein Proteins 0.000 claims description 4
- 101710154606 Hemagglutinin Proteins 0.000 claims description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 4
- 101710176177 Protein A56 Proteins 0.000 claims description 4
- 101710188315 Protein X Proteins 0.000 claims description 4
- 102100021696 Syncytin-1 Human genes 0.000 claims description 4
- LKKIBSZFPLXREY-LYWCUUMRSA-N [[(1r,3r)-1-acetyloxy-4-methyl-1-[4-[[(2r,4s)-4-methyl-1-(4-methylphenyl)-5-oxo-5-[2-[2-(pyridin-4-yldisulfanyl)ethoxycarbonyl]hydrazinyl]pentan-2-yl]carbamoyl]-1,3-thiazol-2-yl]pentan-3-yl]-[(2s,3s)-3-methyl-2-[[(2r)-1-methylpiperidine-2-carbonyl]amino]p Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(=O)NNC(=O)OCCSSC=1C=CN=CC=1)CC=1C=CC(C)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C LKKIBSZFPLXREY-LYWCUUMRSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims description 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 4
- 239000000185 hemagglutinin Substances 0.000 claims description 4
- 229950008141 ozanimod Drugs 0.000 claims description 4
- 229950004058 pimodivir Drugs 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 230000029812 viral genome replication Effects 0.000 claims description 4
- 231100000699 Bacterial toxin Toxicity 0.000 claims description 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 2
- 206010050685 Cytokine storm Diseases 0.000 claims description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 2
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 claims description 2
- 239000002262 Schiff base Chemical group 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims description 2
- 239000000688 bacterial toxin Substances 0.000 claims description 2
- 150000004697 chelate complex Chemical class 0.000 claims description 2
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- LRMHFDNWKCSEQU-UHFFFAOYSA-N ethoxyethane;phenol Chemical group CCOCC.OC1=CC=CC=C1 LRMHFDNWKCSEQU-UHFFFAOYSA-N 0.000 claims description 2
- 150000007857 hydrazones Chemical class 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 229950004244 laninamivir Drugs 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 229960003752 oseltamivir Drugs 0.000 claims description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 2
- 150000002923 oximes Chemical class 0.000 claims description 2
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims description 2
- 229960001084 peramivir Drugs 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 12
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023212681A JP2024029005A (ja) | 2018-07-26 | 2023-12-18 | 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862703534P | 2018-07-26 | 2018-07-26 | |
| US62/703,534 | 2018-07-26 | ||
| US201962846549P | 2019-05-10 | 2019-05-10 | |
| US62/846,549 | 2019-05-10 | ||
| PCT/US2019/042715 WO2020023323A1 (en) | 2018-07-26 | 2019-07-20 | Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023212681A Division JP2024029005A (ja) | 2018-07-26 | 2023-12-18 | 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531312A JP2021531312A (ja) | 2021-11-18 |
| JPWO2020023323A5 true JPWO2020023323A5 (https=) | 2022-07-26 |
| JP2021531312A5 JP2021531312A5 (https=) | 2022-07-26 |
Family
ID=69180703
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021504238A Pending JP2021531312A (ja) | 2018-07-26 | 2019-07-20 | 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体 |
| JP2023212681A Pending JP2024029005A (ja) | 2018-07-26 | 2023-12-18 | 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023212681A Pending JP2024029005A (ja) | 2018-07-26 | 2023-12-18 | 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210393786A1 (https=) |
| EP (1) | EP3826681A4 (https=) |
| JP (2) | JP2021531312A (https=) |
| CN (1) | CN112672762B (https=) |
| AU (1) | AU2019312144B2 (https=) |
| CA (1) | CA3107778A1 (https=) |
| WO (1) | WO2020023323A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021210987A1 (en) * | 2020-01-24 | 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Protein-antiviral compound conjugates |
| US20210402001A1 (en) * | 2020-06-30 | 2021-12-30 | David I. Cohen | Zinc Porters, and their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and Cancers |
| EP4175637A4 (en) * | 2020-07-02 | 2024-08-07 | Purdue Research Foundation | Tetrahydro-3h-pyrazolo quinolone and tetrahydro-3h-pyrrolo[3,2-f]quinoline-containing compounds and uses thereof |
| WO2022015754A2 (en) * | 2020-07-13 | 2022-01-20 | University Of Southern California | Universal car-nk cell targeting various epitopes of hiv-1 gp160 |
| EP4337663A4 (en) * | 2021-05-14 | 2026-04-15 | Purdue Research Foundation | BISPECIFIC SMALL MOLECULE-BASED IMMUNE CELL ATTACHMENTS AND THEIR USE IN THE TREATMENT OF ENVELOPED VIRUS INFECTION |
| MX2024000897A (es) * | 2021-07-28 | 2024-02-06 | Regeneron Pharma | Conjugados de proteina y compuestos antivirales. |
| CN119403574A (zh) * | 2022-04-19 | 2025-02-07 | 普渡研究基金会 | 双半抗原和三半抗原缀合物、组合物、制备方法及其治疗方法 |
| CN116375647A (zh) * | 2023-01-21 | 2023-07-04 | 兰州大学 | 一种基于Click反应的CAR-T细胞药物递送平台及其构建方法与应用 |
| WO2025085664A1 (en) * | 2023-10-17 | 2025-04-24 | Mary Lynn Niedrauer | Conjugates, com positions and methods for treating influenza |
| WO2025133395A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Bicyclic (hetero)arylene wrn inhibitory compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6692724B1 (en) * | 1999-10-25 | 2004-02-17 | Board Of Regents, The University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
| ES2518926T3 (es) * | 2000-06-02 | 2014-11-05 | Board Of Regents, The University Of Texas System | Conjugados de etilendicisteína y un análogo de glucosa |
| WO2002028411A1 (en) * | 2000-10-06 | 2002-04-11 | Xenoport, Inc. | Compounds for sustained release of orally delivered drugs |
| CN102036658A (zh) * | 2008-05-23 | 2011-04-27 | 香港大学 | 治疗流感的联合疗法 |
| CA2790577A1 (en) * | 2010-02-25 | 2011-09-01 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| CN103068378B (zh) * | 2010-05-10 | 2016-07-06 | 中央研究院 | 具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法 |
| US9250238B2 (en) * | 2010-06-25 | 2016-02-02 | Purdue Research Foundation | Pathogen detection |
| US10130714B2 (en) * | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| EP2934532B1 (en) * | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| US10975112B2 (en) * | 2015-06-16 | 2021-04-13 | Hangzhou Dac Biotech Co., Ltd. | Linkers for conjugation of cell-binding molecules |
| JP7282521B2 (ja) * | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
-
2019
- 2019-07-20 CN CN201980056374.6A patent/CN112672762B/zh active Active
- 2019-07-20 AU AU2019312144A patent/AU2019312144B2/en active Active
- 2019-07-20 US US17/263,451 patent/US20210393786A1/en not_active Abandoned
- 2019-07-20 CA CA3107778A patent/CA3107778A1/en active Pending
- 2019-07-20 WO PCT/US2019/042715 patent/WO2020023323A1/en not_active Ceased
- 2019-07-20 JP JP2021504238A patent/JP2021531312A/ja active Pending
- 2019-07-20 EP EP19841376.7A patent/EP3826681A4/en active Pending
-
2023
- 2023-12-18 JP JP2023212681A patent/JP2024029005A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021531312A5 (https=) | ||
| JP4868698B2 (ja) | マクロファージが仲介する疾患の治療および診断 | |
| Elias et al. | Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma | |
| KR102100467B1 (ko) | Ｃｄ33 항체 및 암을 치료하기 위한 이의 용도 | |
| JPWO2020023323A5 (https=) | ||
| Conde et al. | The Aspergillus toxin restrictocin is a suitable cytotoxic agent for generation of immunoconjugates with monoclonal antibodies directed against human carcinoma cells | |
| JPS62181280A (ja) | トリコテセン結合体を含む抗腫瘍剤 | |
| JP2025024041A5 (https=) | ||
| JP2008546792A5 (https=) | ||
| CN107735110A (zh) | 纳米粒子免疫偶联物 | |
| JP2013534528A (ja) | 脂質とコンジュゲートする抗体 | |
| Jagadeesh et al. | Antibody drug conjugates (ADCs): changing the treatment landscape of lymphoma | |
| WO2022040429A3 (en) | Vaccine compositions and antibodies for lyme disease | |
| DePalatis et al. | Lysine Reduces Renal Accumulation of Radioactivity Associated with Injection of the [177Lu] α-[2-(4-Aminophenyl) ethyl]-1, 4, 7, 10-tetraaza-cyclodecane-1, 4, 7, 10-tetraacetic acid-CC49 Fab Radioimmunoconjugate | |
| Dailey et al. | Induction of Cell-Mediated Immunity to Chemically Modified Antigens in Guinea Pigs: I. Characterization of the Immune Response to Lipid-Conjugated Protein Antigens | |
| JPS61197528A (ja) | 免疫毒素製剤 | |
| Scheinberg | Current applications of monoclonal antibodies for the therapy of hematopoietic cancers | |
| JPH0455172B2 (https=) | ||
| JPS62181224A (ja) | 両親媒性分子による抗体物質の処理方法 | |
| CA2333125C (en) | Alpha emitting constructs and uses thereof | |
| US7736651B1 (en) | Alpha emitting constructs and uses thereof | |
| US7166295B1 (en) | Methods of treatment and diagnostic visualization, particularly in cancer | |
| RU2022104765A (ru) | Производные сапонина с улучшенным терапевтическим окном | |
| CN103041387B (zh) | 恶性b细胞淋巴瘤抗体药物的新用途 | |
| Rostaing-Capaillon et al. | Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxins in vivo |